Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Selectivity interaction (KinomeScan (DiscoverX)) EUB0000303b SGK1
Assay data:1 Tested
SummaryRelated BioAssays by Target
Selectivity interaction (Kinase panel (University of Dundee)) EUB0000169b SGK1
Selectivity interaction (Kinase panel (Pfizer) ) EUB0000619a SGK1
Selectivity interaction (Kinase panel (Millipore)) EUB0000153b SGK1
Inhibition of SGK1 (unknown origin) at 1 uM relative to control
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of SGK (unknown origin) in presence of ATP
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of SGK (unknown origin) at 1 uM
SGK DiscoveRx kinase panel
SGK(h) Kinase panel
SGK(h) Millipore kinase panel
Inhibition of SGK1 (unknown origin) at 1 uM
Inhibition of SGK (unknown origin) at 1 uM by kinome scan method
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 500 uM ATP and measured after 60 mins by microfluidics assay
Assay data:55 Active, 9 Activity ≤ 1 nM, 51 Activity ≤ 1 µM, 56 Tested
Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay
Assay data:54 Active, 20 Activity ≤ 1 nM, 54 Activity ≤ 1 µM, 54 Tested
Mobility Shift Assay from US Patent US9365572: "PI3K and/or mTOR inhibitor"
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Enzymatic Activity Assay from US Patent US9221828: "N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides as pharmaceuticals"
Assay data:21 Active, 1 Activity ≤ 1 nM, 20 Activity ≤ 1 µM, 21 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Enzymatic Activity Assay from US Patent US9174993: "N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals"
Assay data:27 Active, 1 Activity ≤ 1 nM, 26 Activity ≤ 1 µM, 27 Tested
Kinase Assay from Article 10.1021/cb300729y: "De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments."
Assay data:2 Active, 6 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Enzymatic Activity Assay from US Patent US9718825: "N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals"
Assay data:625 Active, 8 Activity ≤ 1 nM, 594 Activity ≤ 1 µM, 629 Tested
KinomeScan assay: inhibition of SGK
Assay data:108 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on